901f Efficacy and Safety of Grazoprevir/Elbasvir ± Ribavirin (RBV) for 12 or 16 Weeks in Patients With HCV G1, G4, or G6 Infection Who Previously Failed Peginterferon/RBV: C-EDGE Treatment-Experienced Trial
Paul Y. Kwo(Palo Alto University), Barbara Haber, John M. Vierling(Baylor College of Medicine), Brian L. Pearlman(Atlanta Medical Center), Marı́a Buti(Vall d'Hebron Hospital Universitari), Lawrence Serfaty(Inserm), Cheng‐Yuan Peng(China Medical University), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward Gane(University of Auckland), Jacqueline Gress(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lin Li(Shanghai Jiao Tong University), Eliav Barr(University of New Mexico), Stephen D. Shafran(University of Alberta), Janice Wahl, Paul Stryszak(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 16
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
|Unknown|2006|940